Oglufanide | L-Glutamyl-L-tryptophan | ImmunoModulator | AmBeed-信号通路专用抑制剂

首页 / / / VEGFR / Oglufanide

奥谷法奈 /Oglufanide {[allProObj[0].p_purity_real_show]}

货号：A147248 同义名： L-Glutamyl-L-tryptophan;H-Glu-Trp-OH

Oglufanide是一种血管内皮生长因子（VEGF）抑制剂，能够抑制血管生成。

Oglufanide 化学结构
CAS号：38101-59-6

Oglufanide 3D分子结构
CAS号：38101-59-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Oglufanide 纯度/质量文件产品仅供科研

货号：A147248 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]; • Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]; • JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]; • bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]; • Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]; 更多 >

VEGFR 亚型比较

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	99% (HPLC)
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ VEGFR2, IC50: 25 nM Flk1, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	FGFR,PDGFR,c-Kit	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Fms,c-Kit	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	98%
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		99%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			99%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	99%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	99%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			98%
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	99%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Oglufanide 生物活性

描述

Oglufanide (H-Glu-Trp-OH; L-Glutamyl-L-tryptophan) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections^[2]. Oglufanide effect on survival and spontaneous tumor incidence was studied in female LIO rats. Rats were injected with Oglufanide dissolved in normal saline subcutaneously in a single daily dose 5 µg/animal for 5 consecutive days weekly, during 12 months, starting at the age of 5 months. Mean life span of rats in Oglufanide and control groups was similar but that of 10% maximum survived control rats constituted 949 ± 16.1 days, whereas in the dipeptide-treated rats this value was 1048 ± 21.1 days (P < 0.001). Total tumor incidence was 1.5 times lower (P < 0.01), malignant tumor incidence 1.7 times lower (P < 0.01), and hematopoietic malignancies (leukemias and lymphomas) 3.4 times lower (P < 0.02) in rats exposed to the dipeptide in comparison with controlsAnisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1(1):55-9..

Oglufanide 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00017303	Ovarian Cancer ... 展开 >> Primary Peritoneal Cavity Cancer 收起 <<	Phase 2	Unknown	-	United States, California ... 展开 >> Comprehensive Cancer Center Glendale, California, United States, 91204 Community Hospital of Los Gatos Los Gatos, California, United States, 95032 Stanford University Medical Center Stanford, California, United States, 94305-5408 United States, District of Columbia Lombardi Cancer Center Washington, District of Columbia, United States, 20007 United States, Georgia Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Kansas University of Kansas School of Medicine-Wichita Wichita, Kansas, United States, 67214 United States, Minnesota University of Minnesota Cancer Center Minneapolis, Minnesota, United States, 55455 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198-3330 United States, Nevada Women's Cancer Center - Las Vegas Las Vegas, Nevada, United States, 89030 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263-0001 United States, North Carolina Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina, United States, 27599-7295 United States, Ohio Cleveland Clinic Taussig Cancer Center Cleveland, Ohio, United States, 44195 Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio, United States, 43210-1240 United States, Pennsylvania Magee-Womens Hospital Pittsburgh, Pennsylvania, United States, 15213-3180 United States, Vermont Fletcher Allen Health Care - Medical Center Campus Burlington, Vermont, United States, 05401 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109-1024 University of Washington School of Medicine Seattle, Washington, United States, 98195 United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 收起 <<
NCT00006037	Colorectal Cancer	Phase 2	Terminated(Drug not available)	-	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90033-0804 收起 <<
NCT00003773	Ovarian Cancer	Phase 1	Completed	-	United States, California ... 展开 >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033-0800 收起 <<

Oglufanide 参考文献

[1]Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):411-61.

[2]Kaushik NK, Kaushik N, Attri P, Kumar N, Kim CH, Verma AK, Choi EH. Biomedical importance of indoles. Molecules. 2013 Jun 6;18(6):6620-62

Oglufanide 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.00mL

0.60mL

0.30mL

15.00mL

3.00mL

1.50mL

30.00mL

6.00mL

3.00mL

Oglufanide 技术信息

CAS号	38101-59-6
分子式	C₁₆H₁₉N₃O₅
分子量	333.34

别名	L-Glutamyl-L-tryptophan;H-Glu-Trp-OH;NSC-334073;IM862 NSC 334073;IM 862
运输	蓝冰

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Inert atmosphere,2-8°C

溶解方案

细胞实验：

DMSO: 15 mg/mL(45 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

奥谷法奈 /Oglufanide {[allProObj[0].p_purity_real_show]}

Oglufanide 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Oglufanide 质控信息

Oglufanide 生物活性

Oglufanide 临床研究

Oglufanide 参考文献

Oglufanide 实验方案

Oglufanide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

奥谷法奈 /Oglufanide {[allProObj[0].p_purity_real_show]}

Oglufanide 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Oglufanide 质控信息

Oglufanide 生物活性

Oglufanide 临床研究

Oglufanide 参考文献

Oglufanide 实验方案

Oglufanide 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Oglufanide 纯度/质量文件产品仅供科研